Valory Anne Vailoces | Ophthalmic Pharmacology | Best Researcher Award

Published on 10/06/202510/06/2025 by Top Pharmaceutical

Valory Anne Vailoces | Ophthalmic Pharmacology | Best Researcher Award

Ms. Valory Anne Vailoces, George Washington University School of Medicine & Health Sciences, United States

Ms. Valory Anne Vailoces is a dedicated biomedical scientist and medical student at George Washington University School of Medicine and Health Sciences. She earned her B.S. in Biomedical Sciences from the University of Central Florida in 2021 🎓. Valory conducts impactful ophthalmology research 👁️ under Dr. Michael Tolentino and collaborated with the Miami Itch Center on dermatological studies 🧬. Her pioneering work on rifampicin eye drops for age-related macular degeneration led to a preclinical IND application 💊. She also serves as a senior officer at Hearts for the Homeless International ❤️, combining science with social service.

Publication Profile

Orcid

Education

Valory Anne S. Vailoces earned her B.S. in Biomedical Sciences in 2021 from the University of Central Florida 🧬. She is currently pursuing her medical degree at the George Washington University School of Medicine and Health Sciences 🏥. Alongside her studies, she is actively involved in ophthalmology research 👁️ under the mentorship of Dr. Michael Tolentino. Valory also serves as a senior officer for Hearts for the Homeless International ❤️, a non-profit organization that delivers preventative healthcare services 🩺 to underserved and homeless populations, demonstrating her deep commitment to both science and social impact 🌍.

Professional Memberships

Ms. Valory Anne Vailoces does not currently hold memberships in professional organizations 🤝, her dedication to academic excellence and impactful research in ophthalmology, dermatology, and health management 🧠👁️📊 stands out on its own. Her active involvement in translational research, along with her service to the community through Hearts for the Homeless International ❤️, reflects a strong commitment to both science and humanity 🌍. As she continues to advance in her medical education and research career 🧬, professional affiliations are expected to follow as a natural progression of her growing influence in the field 🚀.

Research Focus

Ms. Valory Anne Vailoces focuses her research on ophthalmology, dermatology, and therapeutic innovation 🧪👁️🧴. Her groundbreaking work includes developing rifampicin eye drops for treating exudative age-related macular degeneration (AMD) 🧬, a major cause of vision loss worldwide 🌍. Additionally, she explores immune-modulating therapeutic nanoparticles for safer clinical applications and leads investigations into aquagenic pruritus, a rare skin condition causing severe itching 💧🧖‍♀️. Through a blend of biomedical science, nanomedicine, and patient-centered studies, Valory contributes to advancing precision treatment modalities with the potential to transform clinical practice 🚀🩺. Her work spans innovative drug delivery and patient quality-of-life research.

Publication Top Notes

Development of Rifampicin Eye Drops for the Treatment of Exudative Age-Related Macular Degeneration

Comprehensive Ocular and Systemic Safety Evaluation of Polysialic Acid-Decorated Immune Modulating Therapeutic Nanoparticles (PolySia-NPs) to Support Entry into First-in-Human Clinical Trials

Aquagenic pruritus: A web‐based survey study exploring itch characteristics, therapeutic options and patient perspectives

Jian Shi | Precision Medicine | Best Researcher Award

Published on 10/06/202510/06/2025 by Top Pharmaceutical

Jian Shi | Precision Medicine | Best Researcher Award

Assoc. Prof. Dr. Jian Shi, Neurology of UCSF, United States

Assoc. Prof. Dr. Jian Shi is a distinguished neuroscientist at the University of California, San Francisco, with a Ph.D. in Neurobiology from Navy Medical University, China. 🧬 He completed postdoctoral training at the University of Texas Southwestern Medical Center, focusing on neuroscience. His research integrates brain injury, neurodegenerative diseases, and glioblastoma with cutting-edge AI and bioinformatics tools. 🧪🧠 Dr. Shi has authored highly cited publications and received numerous accolades, including the APS Outstanding Paper Award. 🌟 A dedicated mentor and educator, he actively contributes to diversity and public service in neurology and biomedical research.

Publication Profile

Google Scholar

Education

Assoc. Prof. Dr. Jian Shi began his academic journey at the National University of Defense Technology in Hunan Province, China, earning both his B.S. and M.S. degrees in Biomechanics. ⚙️📘 He then pursued his Ph.D. in Neurobiology under the mentorship of Dr. Lu Changlin at the prestigious Navy Medical University in Shanghai. 🧬🏥 Driven by a passion for neuroscience, he completed his postdoctoral training at the University of Texas Southwestern Medical Center under the guidance of Dr. Steven G. Kernie, focusing on advanced neuroscience research. 🧠🔬 His academic foundation bridges biomechanics and cutting-edge neurobiological science.

Awards

Assoc. Prof. Dr. Jian Shi has received numerous accolades recognizing his excellence in research and education. 🇨🇳 He was honored with the prestigious National Award for Scientific Progress, Level 2 in China 🥇🔬 and received the Award for Outstanding Scientists from Navy Medical University, where he also earned the Best Teacher Award for his commitment to academic excellence 👨‍🏫🌟. His groundbreaking work earned him the “Top 50 Most Cited Article Award” from the Journal of Clinical Medicine 📖📈 and the APS Outstanding Paper Award from Acta Pharmacologica Sinica 🧪🏅. He is also recognized as a Trusted Reviewer by the International Journal of Molecular Sciences 🧠✅.

Research Focus

Assoc. Prof. Dr. Jian Shi’s research centers around neurobiology, with a strong emphasis on traumatic brain injury (TBI) 🧠💥, neurodegeneration 🧬, neurogenesis 🌱, and molecular neuroscience. His work explores small molecule therapies, microglial activation, intranasal drug delivery 💊, and microRNA biomarkers, particularly in the context of glioblastoma and stroke. He also investigates brain repair mechanisms, exosomal signaling 📦, and neurotrophin-mimetic compounds. In recent years, his interdisciplinary work has extended to climate impact models 🌍 and machine learning applications 🤖 in brain science, reflecting a comprehensive and innovative research portfolio in translational neuroscience and brain health.

Publication Top Notes

Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents

Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor

Intranasal administration with NAD+ profoundly decreases brain injury in a rat model of transient focal ischemia

Considering exosomal miR-21 as a biomarker for cancer

The basic helix-loop-helix transcription factor olig2 is critical for reactive astrocyte proliferation after cortical injury

A small molecule p75^NTR ligand protects neurogenesis after traumatic brain injury

MicroRNAs as biomarkers for human glioblastoma: progress and potential

Regulatory networks between neurotrophins and miRNAs in brain diseases and cancers

Triggering receptor expressed on myeloid cells-2 expression in the brain is required for maximal phagocytic activity and improved neurological outcomes following experimental …

Beneficial effects of minocycline and botulinum toxin–induced constraint physical therapy following experimental traumatic brain injury

Konstantinos Tsapakidis | Immunotherapy | Excellence in Research

Published on 09/06/202509/06/2025 by Top Pharmaceutical

Konstantinos Tsapakidis | Immunotherapy | Excellence in Research

Assist. Prof. Dr. Konstantinos Tsapakidis, University Hospital Of Larissa, Greece

Assist. Prof. Dr. Konstantinos Tsapakidis 🎓👨‍⚕️ is an esteemed Medical Oncologist at the University of Thessaly, Greece. With a Ph.D. focused on prostate cancer research, he holds European Certification in Medical Oncology 🏅. Since 2018, he has been actively involved in clinical oncology, teaching postgraduate courses on cancer, diet, and immunotherapy 🍽️🧬. Dr. Tsapakidis has authored numerous impactful publications 📚, contributing significantly to cancer diagnostics and treatment. Passionate about education, he trains residents and nurses, advancing oncology knowledge. His expertise includes systemic antineoplastic therapies and immune-oncology 🌟.

Publication Profile

Orcid

Education

Assist. Prof. Dr. Konstantinos Tsapakidis 🎓 is a dedicated Medical Oncologist with an impressive educational background. He earned his Biology degree from Aristotelian University of Thessaloniki 🧬 (1998–2002) and completed his Medicine degree at the University of Thessaly 🏥 (2003–2007). Dr. Tsapakidis achieved his Ph.D. with excellence (2005–2012), researching prostate cancer’s cell-cycle and apoptosis mechanisms 🔬. He specialized in Medical Oncology in 2017 🎯 and obtained the prestigious European Certification in Medical Oncology in 2018 🏅. He also enhanced his expertise through an Immune-Oncology e-learning program at the University of Piraeus in 2017–2018 💻.

Experience

Assist. Prof. Dr. Konstantinos Tsapakidis 💼 has extensive medical oncology experience. Since February 2025, he serves as Assistant Professor at the University of Thessaly 🎓. From 2018 to 2025, he worked as Consultant in Medical Oncology at University Hospital of Larissa 🏥. Previously, he was a University Scholar and Fellow Consultant there (2017–2018) 👨‍⚕️. He completed his residency in Medical Oncology (2014–2017) and earlier trained in Internal Medicine and Hematology at Larissa hospitals 🩺. Between 2008–2009, he was a Scientific Associate in Medical Oncology, laying a strong foundation for his clinical career 🔬.

Research Focus

Assist. Prof. Dr. Konstantinos Tsapakidis’s research focus lies primarily in Medical Oncology with a strong emphasis on cancer diagnosis, treatment, and immunotherapy. 🧬🩺 His work explores various cancer types including lung cancer, breast cancer, sarcomas, and rare cancers, investigating immunotherapy responses, molecular diagnostics, and tumor behavior. 🔬💉 He is particularly involved in studying biomarkers like PD-1/PD-L1, immune cell profiling, and novel therapeutic approaches to improve patient outcomes. 🧪⚕️ His research also covers cancer-associated complications like thrombosis and metastatic disease. Overall, his contributions advance personalized oncology care and innovative cancer treatment strategies.

Publication Top Notes

Pseudomyxoma Peritonei: A Challenging Clinical Diagnosis. Case Report and Review of the Literature

The Impact of Expert Pathology Review and Molecular Diagnostics on the Management of Sarcoma Patients: A Prospective Study of the Hellenic Group of Sarcomas and Rare Cancers

Pre-Existing Immunity Predicts Response to First-Line Immunotherapy in Non-Small Cell Lung Cancer Patients

ES-SCLC Patients with PD-L1+ CTCs and High Percentages of CD8+PD-1+T Cells in Circulation Benefit from Front-Line Immunotherapy Treatment

Combinatorial analysis of CD4<SUP>+</SUP>Tregs and CD8<SUP>+</SUP>Teff to predict response to ICI in patients with ES-SCLC

Metachronous Single Pulmonary Metastasis of Prostate Cancer: Report of a Rare Case and Literature Review

SYNCHRONOUS DIAGNOSIS OF TESTICULAR AND THYROID CANCER IN A YOUNG MALE

A Proposed Nomogram Model for Recurrence of Non-Muscle Invasive Bladder Carcinoma COMMENT

Metastatic rectal cancer in the ampulla of Vater: A unique case

Radiotherapy and Breast Reconstruction: What Is the Ideal Timing? A Narrative Review

Effects of a Novel Thiadiazole Derivative with High Anticancer Activity on Cancer Cell Immunogenic Markers: Mismatch Repair System, PD-L1 Expression, and Tumor Mutation Burden

Daniel Bikle | Pharmacogenomics | Best Researcher Award

Published on 09/06/202509/06/2025 by Top Pharmaceutical

Daniel Bikle | Pharmacogenomics | Best Researcher Award

Dr. Daniel Bikle, University of California San Francisoco, United States

Dr. Daniel Bikle 🧬 is a distinguished physician-scientist specializing in endocrinology and bone metabolism. He earned his A.B. magna cum laude from Harvard 🎓 and M.D. from the University of Pennsylvania 🏥, followed by a Ph.D. in Biochemistry. Currently a Professor of Medicine and Dermatology at the University of California, San Francisco 🌉, he has held key research and clinical roles since the 1970s. Dr. Bikle is renowned for his groundbreaking work on vitamin D and bone health ☀️🦴. He has received numerous awards 🏆 and serves on editorial boards and international scientific committees worldwide 🌍.

Publication Profile

Orcid

Education

Dr. Daniel Bikle’s impressive academic journey began at Harvard University 🎓, where he earned his A.B. magna cum laude in Biochemical Sciences in 1965. He then pursued his medical degree (M.D.) at the University of Pennsylvania School of Medicine 🏥, graduating in 1969. Following medical school, he completed an internship and residency at Peter Bent Brigham Hospital in Boston 🏨 from 1969 to 1971, gaining valuable clinical experience. Dr. Bikle deepened his scientific expertise by earning a Ph.D. in Biochemistry at the University of Pennsylvania in 1974 🔬, laying a strong foundation for his distinguished career in medicine and research.

Awards

Dr. Daniel Bikle has received numerous prestigious honors throughout his career 🏅. Starting with the Harvard Honorary Scholarship 🎓 in 1961 and multiple National Science Foundation Fellowships 🔬 during the 1960s, he earned several prizes at Harvard and the University of Pennsylvania, including the Henderson Memorial Prize 🏆 and Horatio C. Wood Prize in Pharmacology 💊. He was awarded fellowships by NIH and professional societies such as the American College of Physicians and Molecular Medicine 🩺. His later accolades include the Boy Frame Award 🦴 in 2007 and the Louis V Avioli Founders Award in 2016, recognizing his excellence in bone and mineral research.

Research Focus

Dr. Daniel Bikle’s research primarily focuses on vitamin D biology, its metabolism, and its critical role in bone health, skin physiology, and immune function 🦴☀️🧬. His extensive work explores vitamin D receptor actions, calcium signaling, and their impact on processes like wound healing and stem cell behavior 🩹🧪. He investigates vitamin D’s role in diseases such as long COVID and lymphoma, and how it influences cellular differentiation and mineral metabolism 🦠💉. Dr. Bikle also studies the molecular mechanisms of vitamin D in skin and bone, making his research essential for endocrinology, dermatology, and metabolic bone disease fields.

Publication Top Notes

Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows

The Role of the Vitamin D Receptor in the Epidermal Stem Cell Response to Wounding

Vitamin D and Long COVID: Is There a Role in Prevention or Treatment?

Mediator 1 ablation induces enamel-to-hair lineage conversion in mice through enhancer dynamics

Mediator 1 ablation induces enamel-to-hair lineage conversion through enhancer dynamics

Role of vitamin D and calcium signaling in epidermal wound healing

Ligand‐Independent Actions of the Vitamin D Receptor: More Questions Than Answers

Decreased Calcium-Sensing Receptor Expression Controls Calcium Signaling and Cell-To-Cell Adhesion Defects in Aged Skin

Introduction: Special Issue on Vitamin D Dedicated to the Memory of Anthony W Norman

The Free Hormone Hypothesis: When, Why, and How to Measure the Free Hormone Levels to Assess Vitamin D, Thyroid, Sex Hormone, and Cortisol Status

Ablation of Ephrin B2 in Col2 Expressing Cells Delays Fracture Repair

Ohidul Alam | Drug Safety and Risk Management | Best Researcher Award

Published on 09/06/202509/06/2025 by Top Pharmaceutical

Ohidul Alam | Drug Safety and Risk Management | Best Researcher Award

Dr. Ohidul Alam, Jiangsu University, China

Dr. Ohidul Alam is an Environmental Engineer specializing in heavy metals, microplastics, and waste management. He earned his Ph.D. from East China University of Science and Technology (2021) and currently works as a Postdoctoral Fellow at Jiangsu University, China. 🔬 His research focuses on eco-friendly wastewater treatment, hazardous waste recycling, and environmental pollution assessment. With expertise in advanced analytical techniques (ICP-MS, XRF) and life cycle assessment, he has published extensively in top environmental journals. 🧪 Passionate about sustainable development and climate change, Dr. Alam actively contributes to environmental awareness through academic writing and collaborative projects worldwide.

Publication Profile

Google Scholar

Education

Dr. Ohidul Alam has a rich academic background in environmental sciences and engineering 🌱. He earned his Ph.D. in Environmental Engineering from the East China University of Science and Technology, Shanghai 🇨🇳 (2016–2021), preceded by an M.Eng. from the UNEP-Tongji Institute for Sustainable Development, Tongji University (2014–2016) 🧪. Earlier, he completed his M.S. and B.Sc. (Hons.) in Environmental Science from the University of Chittagong, Bangladesh 🇧🇩. His foundational education includes HSC from Government City College and SSC from Shilkhali High School in Cox’s Bazar. 🏫 This strong educational journey laid the groundwork for his impactful environmental research 🌏.

Experience

🧑‍🔬 Dr. Ohidul Alam has built an impressive career in environmental research and sustainability 🌿. Currently, he serves as a Post-doctoral Research Fellow at Jiangsu University, China 🇨🇳. His prior roles include Environmental Officer at SEP-IDF and Consultant at DM WATCH and SETS 🏢. His expertise spans hazardous waste, microplastics, climate change, and wastewater treatment 💧. With experience in academic research, project implementation, statistical analysis, and lab techniques like ICP-MS and XRD 🔬, he also writes on environmental topics for leading dailies 📰. Dr. Alam is fluent in Bangla and English and skilled in SPSS and OriginPro 💻.

Awards

Dr. Ohidul Alam has earned several prestigious awards and scholarships for his outstanding academic and research achievements 🌟. He received the Chinese Scholarship Council (CSC) and Marine Scholarship of China (MSC) in 2014 🇨🇳. In 2015, he was honored with Tongji University President Scholarship (2nd prize) 🥈, followed by the Shanghai Municipal Government Scholarship in 2016 🎓. His paper won first prize at the International Student Conference on Environment and Sustainability in 2017 📄🌍. In 2018, he received the ECUST Comprehensive Scholarship (1st prize) for academic excellence and remarkable research contributions .

Research Focus

Dr. Ohidul Alam’s research primarily focuses on environmental science, with a strong emphasis on waste management, environmental pollution, and sustainability. His work explores diverse aspects such as municipal solid waste management, plastic pollution, heavy metals contamination, and eco-friendly remediation technologies. He contributes significantly to understanding the environmental impacts of plastic bags, healthcare waste management, and green business opportunities in Bangladesh. Additionally, Dr. Alam’s recent interests include adsorption techniques for water purification and life cycle assessments. His interdisciplinary research combines chemistry, engineering, and public health to foster a more sustainable and cleaner environment.

Publication Top Notes

An in-depth review on municipal solid waste management, treatment and disposal in Bangladesh

Characteristics of plastic bags and their potential environmental hazards

Determination of the selected heavy metal and metalloid contents in various types of plastic bags

Heavy metals dispersion during thermal treatment of plastic bags and its recovery

Remediation of heavy metals polluted soil environment: A critical review on biological approaches

A preliminary life cycle assessment on healthcare waste management in Chittagong City, Bangladesh

Application of environmental ethics for sustainable development and conservation of Saint Martin s Island in Bangladesh

A deeper look into the inner factors associated to healthcare waste management in Chittagong–the commercial capital of Bangladesh

An investigation into the green business opportunity for the new entrepreneurs in the municipal wastes recycling sector of Bangladesh

Heavy metals detection and removal from contaminated water: A critical review of adsorption methods A critical review on advances in remediation of toxic heavy metals contaminated solids by chemical processes

Takuma Hayashi | Oncology Pharmaceuticals | Best Researcher Award

Published on 09/06/202510/06/2025 by Top Pharmaceutical

Takuma Hayashi | Oncology Pharmaceuticals | Best Researcher Award

Prof. Dr. Takuma Hayashi, National Hospital Organization Kyoto Medical Center, Japan

Prof. Dr. Takuma Hayashi is a renowned Japanese physician-scientist specializing in gynecologic oncology. 🎓 He earned his PhD from the University of Tokyo and trained at MIT’s Whitehead Institute 🧠, contributing to Nobel-linked research. Currently a professor at Shinshu University and Section Head at Kyoto Medical Center 🏥, his groundbreaking work on uterine leiomyosarcoma (LMS) identified LMP2 deficiency as a key biomarker 🔎. Through precision medicine and genomic profiling 🧬, his research has significantly advanced diagnostics and treatment strategies for LMS. With over 30 years of funded research, Dr. Hayashi is globally recognized for revolutionizing women’s cancer care.

Publication Profile

Scopus

Education

Prof. Dr. Takuma Hayashi is a distinguished physician-scientist known for bridging fundamental cancer research with clinical applications. 👨‍⚕️🔬 He is a Professor at Shinshu University Graduate School of Medicine and Section Head at Japan’s National Hospital Organization Kyoto Medical Center. 🎓🏥 Dr. Hayashi earned his PhD from the University of Tokyo and completed postdoctoral training at MIT’s Whitehead Institute under Dr. Rick A. Young. 🎓🇯🇵🇺🇸 He contributed to Nobel Prize-linked AIDS vaccine research with Dr. David Baltimore. With over 30 years of NIH and JSPS funding, his work focuses on molecular research in uterine leiomyosarcoma and ovarian cancer, collaborating with Nobel Laureate Dr. Susumu Tonegawa.

Experience

Prof. Dr. Takuma Hayashi has pioneered precision medicine breakthroughs in uterine leiomyosarcoma (LMS) treatment. 🧬💉 His team used cancer genome panel testing to tailor therapies based on each tumor’s unique genetics. For example, immunotherapy with pembrolizumab led to significant tumor regression, while targeted treatment with pazopanib stabilized disease for months. 🎯💊 Dr. Hayashi’s background from the University of Tokyo and MIT supports his innovative approach. 🚀 His ongoing goals include developing diagnostics, launching clinical trials, expanding global collaboration, and improving patient access to genomic profiling. 🌍💡 His work offers new hope for women facing this aggressive cancer.

Research Focus

Prof. Dr. Takuma Hayashi’s research primarily focuses on molecular oncology and infectious diseases, particularly cancer biomarkers and viral infections. 🧬🔬 His work on uterine leiomyosarcoma involves discovering key diagnostic biomarkers like LMP2 to improve early detection and treatment strategies in aggressive cancers. 🩺🎗️ Additionally, Dr. Hayashi explores infectious diseases such as avian influenza and COVID-19, emphasizing the One Health approach to prevent viral spread between animals and humans. 🦠🌍 His interdisciplinary research bridges cancer biology, immunology, and public health, aiming to develop precision medicine therapies and enhance global disease control efforts.

Publication Top Notes

THE ROLE OF LIVE BIRD MARKETS SHOULD BE EMPHASIZED IN PREVENTING THE SPREAD OF HIGHLY PATHOGENIC AVIAN INFLUENZA INFECTIONS

THE IMPORTANCE OF ONE HEALTH IN PREVENTING THE SPREAD OF HIGHLY PATHOGENIC AVIAN INFLUENZA/H5N1

Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients with Gastric Cancer Associated with Hereditary Breast and Ovarian Cancer

DEVELOPMENT OF ENDOSALPINGIOSIS IN PATIENTS WITH A HISTORY OF BREAST CANCER

High Transferability of Neutralizing Antibodies against SARS-CoV-2 to Umbilical Cord Blood in Pregnant Women Vaccinated with BNT162b2 XBB.1.5: A Retrospective Cohort Study

POTENTIAL DIAGNOSTIC BIOMARKERS FOR HUMAN MESENCHYMAL TUMORS, ESPECIALLY LMP2/Β1I AND CYCLIN E1/MIB1 DIFFERENTIAL EXPRESSION: PRUM-IBIO STUDY

Celine Chaaya | Ophthalmic Pharmacology | Best Researcher Award

Published on 09/06/202509/06/2025 by Top Pharmaceutical

Celine Chaaya | Ophthalmic Pharmacology | Best Researcher Award

Dr. Celine Chaaya, Mass Eye and Ear, United States

Dr. Celine Chaaya 👩‍⚕️, a distinguished medical graduate from the University of Saint-Joseph in Beirut 🇱🇧, earned her Doctorate in Medicine 🎓 (GPA 4.0/4.0) and MSc in Biomechanics and Medical Imaging 🧠. With international clinical exposure at Bascom Palmer Eye Institute 🇺🇸 and a forthcoming postdoctoral fellowship at Massachusetts Eye and Ear 👁️, she excels in ophthalmology and biomechanics research. A dedicated research assistant since 2018 and active in global conferences 🌍, Dr. Chaaya is also a health educator and ambassador 🗣️ for vision awareness. Her commitment to science, education, and innovation makes her a rising star in medical research 🚀.

Publication Profile

Google Scholar

Education

Dr. Celine Chaaya 👩‍⚕️ has demonstrated exceptional academic excellence throughout her educational journey. She recently earned her Doctorate in Medicine 🎓 from the University of Saint-Joseph, Faculty of Medicine in Beirut 🇱🇧, accredited by the World Federation for Medical Education (WFME), graduating with a perfect GPA of 4.0/4.0 🌟. She also holds a Master of Science in Biomechanics and Medical Imaging 🧠, specializing in research and innovation. Her foundational education was completed at the prestigious College Notre Dame de Jamhour 🏫, where she achieved both the French and Lebanese Baccalaureates with the highest honors 🥇, scoring an outstanding 19.6/20 📈.

Experience

Dr. Celine Chaaya 👩‍⚕️ has gained rich clinical experience through diverse medical internships in Lebanon 🇱🇧 and the United States 🇺🇸. At Hôtel-Dieu de France in Beirut, she completed both a Clinical Externship (Nov 2021 – Apr 2022) and is currently engaged in a Clinical Clerkship (Jul 2022 – Present) 🏥, honing her practical skills across various medical disciplines. In January 2023, she undertook a prestigious four-week Clinical Elective at the Bascom Palmer Eye Institute 👁️ in Miami, where she shadowed leading ophthalmologists, attended specialized lectures 🎓, and participated in departmental conferences 🗣️, enriching her global medical perspective 🌍.

Research Focus

Dr. Celine Chaaya’s research focus lies at the intersection of neuroscience 🧠, spinal biomechanics 🦴, ophthalmology 👁️, and public/global health 🌍. Her work spans advanced 3D movement analysis, spinal deformity, and neurodegenerative diseases like Parkinson’s 🧬. She also explores ocular imaging, pediatric ophthalmology, and biomarker-driven diagnostics 🔬. Her interest in mental health impacts during crises 🧘‍♀️ and pharmacotherapy in oncology 💊 reflects a holistic, patient-centered approach. With strong contributions to machine learning in health and international collaborations 📊🤝, Dr. Chaaya’s research is multidimensional, bridging innovation and clinical relevance across multiple medical disciplines.

Publication Top Notes

Ukraine–Russia crisis and its impacts on the mental health of Ukrainian young people during the COVID-19 pandemic

The understanding of Parkinson’s disease through genetics and new therapies

Functional assessment using 3D movement analysis can better predict health-related quality of life outcomes in patients with adult spinal deformity: A machine learning approach

The understanding of Parkinson’s disease through genetics and new therapies, Brain Behav. 12 (5)(2022), e2577

Adverse events of light-assisted hair removal: an updated review

Global malalignment in adolescent idiopathic scoliosis: the axial deformity is the main driver

The understanding of Parkinson’s disease through genetics and new therapies. Brain Behav. 2022; 12 (5): e2577

Head and pelvis are the key segments recruited by adult spinal deformity patients during daily life activities

The Importance of Alignment in the Management of Thoracolumbar Trauma

Global Sagittal Angle and T9-tilt seem to be the most clinically and functionally relevant global alignment parameters in patients with Adult Spinal Deformity

Weak trunk extensors in adult spinal deformity patients are related to sagittal malalignment and kinematic limitations

Salma Khan | Precision Medicine | Best Researcher Award

Published on 03/06/202503/06/2025 by Top Pharmaceutical

Salma Khan | Precision Medicine | Best Researcher Award

Assoc. Prof. Dr. Salma Khan, Loma Linda University, United States

Assoc. Prof. Dr. Salma Khan is a distinguished physician-scientist specializing in gynecologic oncology and thyroid cancer research. With a Ph.D. from Kumamoto University 🇯🇵 and faculty appointments at Loma Linda University 🏥, she excels in translational cancer biology. Her groundbreaking work on health disparities, molecular oncology, and thyroid cancer genomics has earned her multiple honors, including the 2024 AACR Women Cancer Research Award 🌟. She actively contributes to the American Thyroid Association, NIH peer review panels, and serves on several journal editorial boards 📚. Dr. Khan is also a dedicated mentor and advocate for diversity in science and medicine .

Publication Profile

Google Scholar

Education

Assoc. Prof. Dr. Salma Khan began her academic journey with a Higher Secondary Certificate from Govt. M.M. Ali College, Tangail, Bangladesh (1983–1985). 🎓 She earned her MBBS from Gandhi Medical College, Bhopal, India (1986–1991), followed by an internship at Hamidia Hospital (1991–1992). 🏥 Dr. Khan completed her residency in Obstetrics and Gynecology at IPGMR, Dhaka (1992–1994), and pursued a fellowship at Kumamoto University School of Medicine, Japan (1995–1996). 🌸 Her academic excellence culminated in a Ph.D. in Gynecologic Oncology from Kumamoto University (1996–2000), showcasing her dedication to advancing women’s health.

Awards

Assoc. Prof. Dr. Salma Khan has received numerous accolades throughout her distinguished career. She was honored with the Best Mentor Award by BMANA in 2025 (San Francisco), 2023 (Los Angeles), and 2020 (Dallas). 🌟 In 2024, she received the AACR Women Cancer Research Award and the Best Basic Science Research Award in California. 🎗️ A frequent recipient of Travel Awards from the American Thyroid Association (2016–2023), Dr. Khan also earned top honors at scientific meetings and was a keynote speaker in Japan and Korea (2015). 🌍 Her journey began with prestigious academic scholarships in Bangladesh, India, and Japan.

Research Focus

Assoc. Prof. Dr. Salma Khan focuses her research on cancer biology, with a specialized emphasis on exosomes, survivin biology, and biomarkers for early cancer detection, particularly in prostate and breast cancers. Her groundbreaking studies explore how tumor-derived exosomes contribute to cell signaling, apoptosis inhibition, and metastasis, highlighting survivin as a pivotal player and potential diagnostic marker. Dr. Khan’s work intersects molecular oncology and translational medicine, aiming to bridge lab findings with clinical applications. Her contributions are instrumental in advancing non-invasive diagnostic tools and improving cancer prognosis across diverse populations.

Publication Top Notes

Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer

Survivin is released from cancer cells via exosomes

Early diagnostic value of survivin and its alternative splice variants in breast cancer

Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential

PTEN promoter is methylated in a proportion of invasive breast cancers

Human villous macrophage-conditioned media enhance human trophoblast growth and differentiation in vitro

Differential MicroRNA‐Signatures in Thyroid Cancer Subtypes Proteomic profiling of serum-derived exosomes from ethnically diverse prostate cancer patients

Exosomes secreted from human cancer cell lines contain inhibitors of apoptosis (IAP)

LATS1 phosphorylates forkhead L2 and regulates its transcriptional activity

The emerging role of exosomes in survivin secretion

Curcumin induces pancreatic adenocarcinoma cell death via reduction of the inhibitors of apoptosis

Efthalia Zervoudi | Immunotherapy | Best Researcher Award

Published on 03/06/202503/06/2025 by Top Pharmaceutical

Efthalia Zervoudi | Immunotherapy | Best Researcher Award

Dr. Efthalia Zervoudi, Hellenic Pasteur Institute, Greece

Dr. Efthalia Zervoudi is a senior researcher at the Hellenic Pasteur Institute with a PhD in Biochemistry from the University of Athens. Her research focuses on designing inhibitors targeting antigen-trimming aminopeptidases, contributing significantly to immunology and cancer biology. She has extensive experience in oncology and molecular biomarkers, having held positions at Cardiff University and University Hospital “Attikon.” Dr. Zervoudi has authored multiple influential publications and holds patents on aminopeptidase inhibitors. She has received prestigious fellowships, including the Welcome Trust ISSF fellowship, and continues to advance personalized medicine through innovative molecular diagnostic approaches.

Publication Profile

Google Scholar

Education

I completed my PhD in Biochemistry at the University of Athens (2012–2016) with top honors, focusing on designing inhibitors targeting antigen-trimming aminopeptidases. Before that, I earned my Master’s degree in Biochemistry from the same university (2010–2012), studying the specificity pockets of aminopeptidases involved in antigen processing. My academic journey began with a Bachelor’s degree in Chemistry from the University of Patras (2003–2008), where I researched proteoglycans in cancer patients under Prof. Dimitrios Vynios. 🎓 Prior to university, I graduated high school with a strong average score of 18.5/20, marking the start of my scientific path.

Experience

Dr. Efthalia Zervoudi is currently serving as a Senior Researcher at the Hellenic Pasteur Institute (2024–present), contributing to cutting-edge biomedical research. From 2019 to 2023, she was a Research Coordinator at the Oncology Unit of University Hospital “Attikon” in Greece. 🏥 Previously, she held a postdoctoral research position at Cardiff University’s School of Medicine (2016–2019), specializing in Infection and Immunity. 🔬 Between 2010 and 2015, she collaborated with the Protein Chemistry Lab at the National Centre for Scientific Research “DEMOKRITOS”, working on the project: “Rational design and development of inhibitors for targeting antigen-trimming aminopeptidases.”

Awards

Dr. Efthalia Zervoudi has received several prestigious fellowships and awards recognizing her impactful research. In 2020, she was awarded funding by the Hellenic Society of Oncology for her study on Endoplasmic Reticulum Associated Peptidases as tools to understand cancer. 🧪 In 2015, she received the esteemed Wellcome Trust ISSF Fellowship at Cardiff University. 🇬🇧 Earlier, in Fall 2014, the Hellenic Academy of Athens honored her with the “Axillea and Aikaterini Dionysopoulou” award for her groundbreaking work on rationally designed inhibitors enhancing antigen presentation and cytotoxic T-cell responses. 🔬🎖️ Her research continues to push scientific boundaries.

Research Focus

Dr. Efthalia Zervoudi is a leading researcher in immunology and molecular biology, with a focus on antigen processing, immune regulation, and aminopeptidase function. Her work explores how enzymes like ERAP1 and ERAP2 trim antigenic peptides for presentation by MHC class I molecules, enhancing cytotoxic T-cell responses—a crucial process in cancer immunotherapy and autoimmune disease research. 🧬 She also develops targeted inhibitors to modulate immune responses, contributing to vaccine design and tumor immunity. 🧪 Her research bridges biochemistry, structural biology, and immuno-oncology, with potential applications in personalized medicine.

Publication Top Notes

Rationally designed inhibitor targeting antigen-trimming aminopeptidases enhances antigen presentation and cytotoxic T-cell responses

Probing the S1 specificity pocket of the aminopeptidases that generate antigenic peptides

A common single nucleotide polymorphism in endoplasmic reticulum aminopeptidase 2 induces a specificity switch that leads to altered antigen processing

Optimized peptide–MHC multimer protocols for detection and isolation of autoimmune T-cells

A role for naturally occurring alleles of endoplasmic reticulum aminopeptidases in tumor immunity and cancer pre-disposition

Autoimmune disease-associated variants of extracellular endoplasmic reticulum aminopeptidase 1 induce altered innate immune responses by human immune cells

3, 4-diaminobenzoic acid derivatives as inhibitors of the oxytocinase subfamily of M1 aminopeptidases with immune-regulating properties

Novel selective inhibitors of aminopeptidases that generate antigenic peptides

Dual molecular mechanisms govern escape at immunodominant HLA A2-restricted HIV epitope

A common SNP in ER aminopeptidase 2 induces a specificity switch that leads to altered antigen processing

HPV16 E6 Oncogene Contributes to Cancer Immune Evasion by Regulating PD-L1 Expression through a miR-143/HIF-1a Pathway

Correction: Konstantopoulos et al. HPV16 E6 Oncogene Contributes to Cancer Immune Evasion by Regulating PD-L1 Expression through a miR-143/HIF-1a Pathway. Viruses 2024, 16, 113

SILVIA MARIA DÍAZ PRADO | Drug Delivery Systems | Lifetime achievement Award

Published on 03/06/202503/06/2025 by Top Pharmaceutical

SILVIA MARIA DÍAZ PRADO | Drug Delivery Systems | Lifetime achievement Award

Prof. Dr. SILVIA MARIA DÍAZ PRADO, University of A Coruña, Spain

Prof. Dr. Silvia María Díaz Prado is a Professor of Anatomy at the University of A Coruña and leads the Cellular Therapy and Regenerative Medicine Group at INIBIC. With a PhD in Biology (2004), her research spans tissue engineering, stem cells 🧬 (including iPSCs), novel biomaterials, 3D bioprinting 🖨️, and nanoparticle drug delivery 💊. She has published 68 articles (H-index: 24), 32 book chapters, and presented at 215 conferences. Dr. Díaz Prado has led 33 research projects, supervised over 50 theses, and received 7 research awards 🏅. She coordinates the Master’s in Health Care and Research program.

Publication Profile

Google Scholar

Education

Prof. Dr. Silvia María Díaz Prado 🎓 holds a Ph.D. in Biology (2004) from the University of A Coruña, where she serves as a Professor of Anatomy 🧠 and coordinates the Master’s Degree in Health Care and Research 💉📚. With a distinguished academic career, she has played a pivotal role in shaping advanced medical education and fostering scientific inquiry 🔬. Her dedication to teaching and mentorship has inspired countless students and researchers, reinforcing her status as a respected leader in the biomedical field 🌟. Prof. Dr. Díaz Prado continues to advance excellence in health sciences through education and innovation.

Awards

Prof. Dr. Silvia María Díaz Prado 🏅 has been honored with seven prestigious research awards 🧪, reflecting the high regard in which her scientific contributions are held by the academic community 🌍. These accolades underscore her exceptional merit, dedication to innovation, and impactful work in the field of biomedical research 🧬. Each award stands as a testament to her relentless pursuit of knowledge, excellence, and advancement in science 🔍✨. Prof. Díaz Prado’s achievements not only bring recognition to her individual efforts but also elevate the institutions and research teams she represents, inspiring future generations of scientists 🎓🌟.

Research Focus

Prof. Dr. Silvia María Díaz-Prado is a distinguished researcher in the field of Regenerative Medicine 🧬🦴, with a strong focus on stem cells, cartilage repair, and molecular signaling in musculoskeletal disorders. Her groundbreaking work explores microRNA profiling🧪, mesenchymal stem cells🧫, and the human amniotic membrane as a novel source for cell therapy. She also investigates oncogenic pathways like Wnt, Notch, and Hedgehog 🔬, linking them to cancer stem cells. Prof. Díaz-Prado’s contributions bridge molecular biology with clinical applications, making her a key figure in orthopedic tissue engineering, biomarkers, and cell-based therapeutic strategies.